TEM: Data Partnerships And Backlog Will Support Future Oncology Data Upside

Tempus AI's analyst price target is now $67.20, down from $72.40, as analysts adjust their models to reflect more moderate revenue growth assumptions and mixed recent price target revisions across the Street.

Analyst Commentary

Recent research on Tempus AI shows a mix of optimism and caution as analysts update their models, adjust price targets, and refine views following Q4 results and new coverage initiations.

Bullish Takeaways

Bullish analysts highlight Tempus AI's position in precision oncology diagnostics and AI-enabled healthcare data services, pointing to a large total addressable market and the potential for the company to grow at or above market rates over the next few years.
Some research points to a US$1.1b data backlog as an important support for the company's data platform business, which bullish analysts see as a foundation for long term growth and a reason to keep investing in the platform.
Several firms maintain Outperform or Buy ratings even when trimming price targets, pointing to ongoing expansion of partnerships with large pharmaceutical groups and academic centers as important for Tempus AI's competitive position and future execution.
Where models have been updated after Q4 results, bullish analysts generally frame those results as in line with expectations, with management reiterating medium term outlook targets that underpin their valuation work.

Bearish Takeaways

Bearish analysts focus on the series of price target reductions across the Street, which they view as a sign that prior expectations may have been too aggressive relative to current execution and revenue visibility.
JPMorgan flags what it calls "clouded visibility" on data upside and a shift in the Ambry outlook, using this as a reason to stay on the sidelines and to support a Neutral rating with a lower price target.
Multiple firms keep Hold or equivalent ratings while cutting targets, indicating concern that recent stock volatility, valuation resets, and uncertainty around the pace of monetizing data and services could limit near term upside.
Some cuts reference broader market pullbacks and valuation pressure, suggesting that even with attractive end markets, investors may be less willing to pay prior multiples until Tempus AI shows clearer traction against its long term plans.

What's in the News

Tempus AI, Inc. increased full year 2026 revenue guidance to a range of US$1.59b to US$1.60b, which the company states represents about 25% annual growth.
Lucent Diagnostics and Tempus AI agreed to collaborate on expanding access to an Alzheimer's blood-based biomarker panel through a Tempus Next care gap program and Tempus' clinical ordering platform.
Tempus AI and the Keck School of Medicine of USC and Keck Medicine of USC announced a collaboration to bring AI driven clinical testing, trial matching, care gap pathways, and research programs into care across more than 1.5 million annual patient visits.
Tempus AI and Gilead Sciences agreed to expand a multi year collaboration that gives Gilead enterprise wide access to Tempus' AI driven Lens platform and broader multimodal datasets to support oncology research.
The U.S. Food and Drug Administration is turning to AI to help speed up clinical trials, which is relevant for Tempus AI as an AI focused healthcare data and diagnostics company (Wall Street Journal).

Valuation Changes

Fair Value: The analyst fair value estimate moved from $72.40 to $67.20, a reduction of about 7.2%.
Discount Rate: The discount rate edged down from 8.10% to 7.97%, a small adjustment in the risk assumption used in the model.
Revenue Growth: The forecast revenue growth rate shifted from 22.07% to 20.39%, a modest step down in projected top line expansion.
Net Profit Margin: The assumed net profit margin increased slightly from 15.41% to 15.62%, implying a small improvement in expected profitability.
Future P/E: The assumed future P/E multiple moved from 50.27x to 45.50x, indicating a lower valuation multiple applied to forward earnings.

12 views

Key Takeaways

Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage.
Expanding clinical-genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long-term growth opportunities.
Rising competition, reimbursement uncertainty, regulatory hurdles, and ongoing investment needs threaten Tempus AI's margins, revenue growth, and progress toward sustainable profitability.

Catalysts

About Tempus AI

Operates as a healthcare technology company.What are the underlying business or industry changes driving this perspective?

Significant volume growth and market share gains in both oncology and hereditary/genetic testing indicate that Tempus AI is leveraging its expanding data repository and technological differentiation to outperform competitors, positioning the company for durable top-line revenue growth.
Tempus AI's large-scale partnerships with biopharma (e.g., AstraZeneca Pathos foundation model) demonstrate rising demand for AI-driven insights amid growing healthcare data complexity, likely driving recurring data licensing revenue and supporting overall earnings stability.
The ongoing expansion of clinical-genomic integrations-such as Tempus' broad MRD and liquid biopsy portfolios-means that, upon future reimbursement, there is further upside to both volume and revenue, with potential positive impact on net margins due to greater operating leverage on fixed R&D costs.
Robust discipline in investment and operating leverage, as evidenced by rapid revenue growth paired with improving adjusted EBITDA and gross margins, supports near-term profitability and strengthens the case for long-term scalable earnings expansion.
Secular increases in the adoption of AI and data analytics in drug development, along with broadening regulatory clarity for digital diagnostics, suggest Tempus AI is uniquely positioned to capture a growing share of healthcare spending, directly increasing revenue and fortifying future margin improvement opportunities.

Tempus AI Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Tempus AI's revenue will grow by 20.4% annually over the next 3 years.
Analysts are not forecasting that Tempus AI will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Tempus AI's profit margin will increase from -22.2% to the average US Life Sciences industry of 15.6% in 3 years.
If Tempus AI's profit margin were to converge on the industry average, you could expect earnings to reach $371.7 million (and earnings per share of $1.86) by about May 2029, up from -$302.9 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 45.6x on those 2029 earnings, up from -27.8x today. This future PE is greater than the current PE for the US Life Sciences industry at 32.0x.
Analysts expect the number of shares outstanding to grow by 3.72% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.97%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Intensifying competition in both the genomics diagnostics and AI data space, including large, well-capitalized incumbents and new entrants, could drive down average selling prices (ASPs) and result in margin compression, impacting Tempus AI's long-term net margins and earnings.
Delays and uncertainty around reimbursement for new assays-particularly in liquid biopsy, MRD (minimal residual disease), and AI-driven diagnostics-may constrain revenue growth and limit the scale-up of higher-margin, innovative offerings.
Escalating regulatory scrutiny and slow progress on clear reimbursement pathways for purely AI-driven algorithms (as noted for non-lab-based insights) could result in under-monetization of Tempus's AI investments, dampening longer-term revenue and free cash flow.
Large pharma clients are still making substantial investments in data and AI, but commentary signals potential vulnerability to market downturns or R&D budget cuts in the biotech/pharma industry, which could impact Tempus AI's recurring revenue from data and insights licensing.
Ongoing requirement for significant R&D and capex investment in infrastructure, foundational models, and product expansion-without corresponding, sustained revenue growth-risks the company outpacing its operating margin improvements and delaying achievement of durable cash flow positivity.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $67.2 for Tempus AI based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of just $35.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.4 billion, earnings will come to $371.7 million, and it would be trading on a PE ratio of 45.6x, assuming you use a discount rate of 8.0%.
Given the current share price of $46.95, the analyst price target of $67.2 is 30.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Tempus AI?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Advances In Precision Medicine And AI Will Reshape Cancer Care Futures